Oncolytics Biotech Inc T.ONC

Today's Clinical Results Seem Promising

[markymark11]

Today's clinical update seems promising compared to other trials done in advanced pancreatic cancer.

 

In a study using acalabrutinib alone or with pembrolizumab, the overall response rate and disease control rate were 0% and 14.3% with monotherapy and 7.9% and 21.1% with combination therapy, respectively. [1]

Another study, using Durvalumab with or without Tremelimumab, reported an overall response rate of 3.1% for patients treated with combination therapy and 0% for patients treated with monotherapy. The disease control rate at 3 months was 9.4% for patients treated with combination therapy and 6.1% for patients treated with monotherapy. [2]

 

Oncolytics reports that their study achieved a disease control rate of 42%. I look forward to reading the full poster presentation when it's released in June.


[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057435 - Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647002 - Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

[askretka]

Yep! Big Pharma has the eggs. Oncolytics Biotech has the BACON, and big pharma wants BACON to go with their eggs! Can't make it any simpler than that for anyone who want to invest. Cheers!

[fox7mf]

Agreed 100%, which is why I'm inclined to believe buyout talks with Big Pharma are in motion and a deal could come anytime within the next few months. The science saves lives...the price will reflect that. IMO.

[Capitalista]

Mmmmmmmm.  Bacon!